Inventor: William D. Huse

Serial No. 09/016,061

Filed: January 30, 1998

APPENDIX A

In the specification:

On page 116, please delete the abstract on lines 2-29 and substitute therefor:

[The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to $\alpha_{\nu}\beta_{3}$. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof.] The invention [additionally] provides a [high affinity] LM609 grafted antibody comprising one or more CDRs having at least one amino acid substitution, where the <u>LM609 grafted antibody has</u> $\alpha_v \beta_3$ binding activity [of the high affinity LM609 grafted antibody is enhanced]. Nucleic acids encoding [Vitaxin and] LM609 grafted heavy and light chains [as well as nucleic acids encoding the parental non-human antibody LM609] are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of $\alpha_{\nu}\beta_{3}$. The method consists of contacting $\alpha_{\nu}\beta_{3}$ with [Vitaxin or] a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to $\alpha_{\nu}\beta_{3}$. Finally, the invention provides for a method of treating an $\alpha_v \beta_3$ -mediated

Inventor:

William D. Huse

Serial No.:

09/016,061

Filed:

January 30, 1998

disease. The method consists of administering an effective amount [of Vitaxin or] a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to $\alpha_{\nu}\beta_{3}$.

In the claims:

Please amend the claims as follows:

105. (Amended) The [enhanced] <u>high affinity</u> LM609 grafted antibody of claim 74, wherein said [enhanced] <u>high</u>

<u>affinity</u> LM609 grafted antibody has an increased association rate relative to parental LM609 grafted antibody.

106. (Amended) The [enhanced] <u>high affinity</u> LM609 grafted antibody of claim 74, wherein said enhanced LM609 grafted antibody has a decreased dissociation rate relative to parental LM609 grafted antibody.